University of Oulu

Laitakari, A., Tapio, J., Mäkelä, K.A. et al. HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD. J Mol Med 98, 719–731 (2020). https://doi.org/10.1007/s00109-020-01903-0

HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD

Saved in:
Author: Laitakari, Anna1; Tapio, Joona1; Mäkelä, Kari A.2;
Organizations: 1Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, Oulu Center for Cell-Matrix Research, University of Oulu, Aapistie 7C, FIN-90014, Oulu, Finland
2Research Unit of Biomedicine, Biocenter Oulu, Medical Research Center and University Hospital, Oulu, Finland
3Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland
4University of Leipzig, Leipzig, Germany
5Internal Medicine, University of Helsinki and Helsinki University Hospital, 00029 HUS, Helsinki, Finland
6FibroGen, Inc., San Francisco, CA, USA
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 8.9 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe2020070246723
Language: English
Published: Springer Nature, 2020
Publish Date: 2020-07-02
Description:

Abstract

Non-alcoholic fatty liver disease (NAFLD) parallels the global obesity epidemic with unmet therapeutic needs. We investigated whether inhibition of hypoxia-inducible factor prolyl 4-hydroxylase-2 (HIF-P4H-2), a key cellular oxygen sensor whose inhibition stabilizes HIF, would protect from NAFLD by subjecting HIF-P4H-2-deficient (Hif-p4h-2gt/gt) mice to a high-fat, high-fructose (HFHF) or high-fat, methionine-choline-deficient (HF-MCD) diet. On both diets, the Hif-p4h-2gt/gt mice gained less weight and had less white adipose tissue (WAT) and its inflammation, lower serum cholesterol levels, and lighter livers with less steatosis and lower serum ALT levels than the wild type (WT). The intake of fructose in majority of the Hif-p4h-2gt/gt tissues, including the liver, was 15–35% less than in the WT. We found upregulation of the key fructose transporter and metabolizing enzyme mRNAs, Slc2a2, Khka, and Khkc, and higher ketohexokinase activity in the Hif-p4h-2gt/gt small intestine relative to the WT, suggesting enhanced metabolism of fructose in the former. On the HF-MCD diet, the Hif-p4h-2gt/gt mice showed more browning of the WAT and increased thermogenesis. A pharmacological pan-HIF-P4H inhibitor protected WT mice on both diets against obesity, metabolic dysfunction, and liver damage. These data suggest that HIF-P4H-2 inhibition could be studied as a novel, comprehensive treatment strategy for NAFLD.

see all

Series: Journal of molecular medicine
ISSN: 0946-2716
ISSN-E: 1432-1440
ISSN-L: 0946-2716
Volume: 98
Issue: 5
Pages: 719 - 731
DOI: 10.1007/s00109-020-01903-0
OADOI: https://oadoi.org/10.1007/s00109-020-01903-0
Type of Publication: A1 Journal article – refereed
Field of Science: 1182 Biochemistry, cell and molecular biology
Subjects:
HIF
Funding: This study was supported by the Academy of Finland grants 266719 and 308009 (PK), and 296498 (JM), the Academy of Finland Center of Excellence 2012–2017 grant 251314 (JM), and grants from the S. Jusélius Foundation (PK and JM), the Finnish Cancer Organization (PK), and the Jane and Aatos Erkko Foundation (PK and JM).
Academy of Finland Grant Number: 266719
308009
296498
251314
Detailed Information: 266719 (Academy of Finland Funding decision)
308009 (Academy of Finland Funding decision)
296498 (Academy of Finland Funding decision)
251314 (Academy of Finland Funding decision)
Copyright information: © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
  https://creativecommons.org/licenses/by/4.0/